Wednesday, November 25, 2009, 10:09am EST - Canadian Markets close in 5 hours and 51 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Santarus Inc. (SNTS)

 At 09:54 EST: 4.02 USD  Down 0.09 (2.19%)  
MORE ON SNTS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade: 4.02 USD
Trade Time: 9:54AM EST
Change: Down 0.09 (2.19%)
Prev Close: 4.11
Open: 4.14
Bid: 4.02 x 100
Ask: 4.03 x 400
1y Target Est: 4.83
Day's Range: 4.01 - 4.12
52wk Range: 1.05 - 4.23
Volume: 34,908
Avg Vol (3m): 252,118
Market Cap: 233.46M
P/E (ttm): N/A
EPS (ttm): -0.05
Div & Yield: N/A (N/A%)
Santarus Inc. (SNTS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SNTS to Portfolio   Download Data

HEADLINES
• Santarus to Present at Piper Jaffray 21st Annual Health Care Conference
Business Wire (Tue 4:01am)
• Santarus' Zegrid Facing Back-to-Back FDA Approval Dates
at Seeking Alpha (Fri, Nov 20)
• Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
at Seeking Alpha (Mon, Nov 16)
• [$$] Biotech Stock Mailbag: Cardium Therapeutics
at RealMoney by TheStreet.com (Fri, Nov 13)
• SANTARUS INC Financials
EDGAR Online Financials (Tue, Nov 10)
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Nov 10)
• Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Business Wire (Tue, Nov 10)
• Santarus Reports Strong Quarter
Zacks.com (Sat, Nov 7)
• New Star Analyst Rankings for Santarus, Inc.
StarMine (Thu, Nov 5)
• Santarus Inc. Q3 2009 Earnings Call Transcript
at Seeking Alpha (Wed, Nov 4)
• Santarus, Inc. Earnings Call scheduled for 5:00 pm ET today
CCBN (Wed, Nov 4)
• Santarus Reports Third Quarter 2009 Financial Results
Business Wire (Wed, Nov 4)
• SANTARUS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Wed, Nov 4)
More Headlines for SNTS...
ANALYST
EPS Est (next year) (Dec-09) : 0.26
EPS Est (in 2 years) (Dec-10) : 0.24
Avg Rec (current)*: 2.5
PEG Ratio: 1.44
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices